Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects

What Was Tested

Researchers studied Peptide YY in this randomized controlled trial publication.

In contrast with peripheral infusion, oral delivery of sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) mimics endogenous secretion.

The researchers aimed to investigate how this affects food intake.

Why It Was Studied

In vivo, both peptides are cosecreted from intestinal L cells; GLP-1 is subject to rapid breakdown by dipeptidyl peptidase IV, and together with PYY3-36 it is likely to be degraded in the liver before entering the systemic circulation.

The largest concentrations are observed in the splanchnic blood rather than in the systemic circulation.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

The placebo treatment was the delivery agent alone.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Peptide YY study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Peptide YY, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Peptide YY group a baseline to be compared against.

In the crossover set-up each of the participants took both Peptide YY and the comparison in turn, acting as their own control.

Food intake during an ad libitum test meal was measured.

What Was Measured

In vivo, both peptides are cosecreted from intestinal L cells; GLP-1 is subject to rapid breakdown by dipeptidyl peptidase IV, and together with PYY3-36 it is likely to be degraded in the liver before entering the systemic circulation.

The subject headings attached to it are Eating, Energy Metabolism, Glucagon-Like Peptide 1, Hunger, Peptide Fragments, Peptide YY and Satiation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptide YY.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (The American journal of clinical nutrition), a journal based in United States.

More context: the Peptide YY compound page, all human trials.